Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 122 entries
Sorted by: Best Match Show Resources per page
A Sensitive Precolumn Derivatization Method for Determination of Piperazine in Vortioxetine Hydrobromide Using a C8 Column and High-Performance Liquid Chromatography-Mass Spectrometry.

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry

Dong S, Yan Z, Yang H.
PMID: 27941264
Anal Sci. 2016;32(12):1333-1338. doi: 10.2116/analsci.32.1333.

A rapid and sensitive high-performance liquid chromatography-mass spectrometry method was established to determine the trace residues of piperazine in vortioxetine hydrobromide. The presence of piperazine was determined by precolumn derivatization with dansyl chloride. Chromatographic separation was performed on a...

Cite
Dong S, Yan Z, Yang H. A Sensitive Precolumn Derivatization Method for Determination of Piperazine in Vortioxetine Hydrobromide Using a C8 Column and High-Performance Liquid Chromatography-Mass Spectrometry. Anal Sci. 2016;32(12):1333-1338doi: 10.2116/analsci.32.1333.
Dong, S., Yan, Z., & Yang, H. (2016). A Sensitive Precolumn Derivatization Method for Determination of Piperazine in Vortioxetine Hydrobromide Using a C8 Column and High-Performance Liquid Chromatography-Mass Spectrometry. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 32(12), 1333-1338. https://doi.org/10.2116/analsci.32.1333
Dong, Shubo, et al. "A Sensitive Precolumn Derivatization Method for Determination of Piperazine in Vortioxetine Hydrobromide Using a C8 Column and High-Performance Liquid Chromatography-Mass Spectrometry." Analytical sciences : the international journal of the Japan Society for Analytical Chemistry vol. 32,12 (2016): 1333-1338. doi: https://doi.org/10.2116/analsci.32.1333
Dong S, Yan Z, Yang H. A Sensitive Precolumn Derivatization Method for Determination of Piperazine in Vortioxetine Hydrobromide Using a C8 Column and High-Performance Liquid Chromatography-Mass Spectrometry. Anal Sci. 2016;32(12):1333-1338. doi: 10.2116/analsci.32.1333. PMID: 27941264.
Copy Download .nbib Format: NLM
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS.
PMID: 27725683
Neuropsychopharmacology. 2016 Nov;41(12):2961. doi: 10.1038/npp.2016.181.

No abstract available.

Cite
Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2016;41(12):2961doi: 10.1038/npp.2016.181.
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2016). A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 41(12), 2961. https://doi.org/10.1038/npp.2016.181
Mahableshwarkar, Atul R, et al. "A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol. 41,12 (2016): 2961. doi: https://doi.org/10.1038/npp.2016.181
Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2016 Nov;41(12):2961. doi: 10.1038/npp.2016.181. PMID: 27725683; PMCID: PMC5061887.
Copy Download .nbib Format: NLM
Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?.

Clinical practice and epidemiology in mental health : CP & EMH

Carta MG, Pala AN, Finco G, Musu M, Moro MF.
PMID: 25893002
Clin Pract Epidemiol Ment Health. 2015 Feb 27;11:144-9. doi: 10.2174/1745017901511010144. eCollection 2015.

INTRODUCTION: Depression and cerebrovascular atherosclerosis often occur in comorbidity showing neuropsychological impairment and poor response to antidepressant treatment. Objective is to evaluate if new antidepressant vortioxetine may be a potential treatment option. Mechanism of Action : Vortioxetine has 5-HT3,...

Cite
Carta MG, Pala AN, Finco G, et al. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?. Clin Pract Epidemiol Ment Health. 2015;11:144-9doi: 10.2174/1745017901511010144.
Carta, M. G., Pala, A. N., Finco, G., Musu, M., & Moro, M. F. (2015). Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?. Clinical practice and epidemiology in mental health : CP & EMH, 11144-9. https://doi.org/10.2174/1745017901511010144
Carta, Mauro Giovanni, et al. "Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?." Clinical practice and epidemiology in mental health : CP & EMH vol. 11 (2015): 144-9. doi: https://doi.org/10.2174/1745017901511010144
Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?. Clin Pract Epidemiol Ment Health. 2015 Feb 27;11:144-9. doi: 10.2174/1745017901511010144. eCollection 2015. PMID: 25893002; PMCID: PMC4397833.
Copy Download .nbib Format: NLM
The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.

Neuropsychiatric disease and treatment

Li G, Wang X, Ma D.
PMID: 27013879
Neuropsychiatr Dis Treat. 2016 Feb 29;12:523-31. doi: 10.2147/NDT.S103173. eCollection 2016.

BACKGROUND: Vortioxetine is an investigational multimodal antidepressant. We conducted this meta-analysis to assess the efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder (MDD).METHODS: Randomized controlled trials (RCTs) published in PubMed, Web of Science,...

Cite
Li G, Wang X, Ma D. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016;12:523-31doi: 10.2147/NDT.S103173.
Li, G., Wang, X., & Ma, D. (2016). The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatric disease and treatment, 12523-31. https://doi.org/10.2147/NDT.S103173
Li, Guangjian, et al. "The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials." Neuropsychiatric disease and treatment vol. 12 (2016): 523-31. doi: https://doi.org/10.2147/NDT.S103173
Li G, Wang X, Ma D. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016 Feb 29;12:523-31. doi: 10.2147/NDT.S103173. eCollection 2016. PMID: 27013879; PMCID: PMC4778778.
Copy Download .nbib Format: NLM
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.

Therapeutics and clinical risk management

Kelliny M, Croarkin PE, Moore KM, Bobo WV.
PMID: 26316764
Ther Clin Risk Manag. 2015 Aug 12;11:1193-212. doi: 10.2147/TCRM.S55313. eCollection 2015.

This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy...

Cite
Kelliny M, Croarkin PE, Moore KM, et al. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag. 2015;11:1193-212doi: 10.2147/TCRM.S55313.
Kelliny, M., Croarkin, P. E., Moore, K. M., & Bobo, W. V. (2015). Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and clinical risk management, 111193-212. https://doi.org/10.2147/TCRM.S55313
Kelliny, Marc, et al. "Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature." Therapeutics and clinical risk management vol. 11 (2015): 1193-212. doi: https://doi.org/10.2147/TCRM.S55313
Kelliny M, Croarkin PE, Moore KM, Bobo WV. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag. 2015 Aug 12;11:1193-212. doi: 10.2147/TCRM.S55313. eCollection 2015. PMID: 26316764; PMCID: PMC4542474.
Copy Download .nbib Format: NLM
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.

Neuropsychiatric disease and treatment

Katona CL, Katona CP.
PMID: 24570588
Neuropsychiatr Dis Treat. 2014 Feb 19;10:349-54. doi: 10.2147/NDT.S39544. eCollection 2014.

Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies...

Cite
Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:349-54doi: 10.2147/NDT.S39544.
Katona, C. L., & Katona, C. P. (2014). New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatric disease and treatment, 10349-54. https://doi.org/10.2147/NDT.S39544
Katona, Cornelius L, and Katona, Cara P. "New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder." Neuropsychiatric disease and treatment vol. 10 (2014): 349-54. doi: https://doi.org/10.2147/NDT.S39544
Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014 Feb 19;10:349-54. doi: 10.2147/NDT.S39544. eCollection 2014. PMID: 24570588; PMCID: PMC3933721.
Copy Download .nbib Format: NLM
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.

Annals of general psychiatry

Shah A, Northcutt J.
PMID: 29760763
Ann Gen Psychiatry. 2018 May 11;17:19. doi: 10.1186/s12991-018-0190-6. eCollection 2018.

BACKGROUND: Despite the current treatments available for panic disorder (PD), as many as one-third of patients have persistent and treatment-resistant panic attacks. Vortioxetine is an approved medicine for major depressive disorder and has been shown to have anxiolytic properties....

Cite
Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry. 2018;17:19doi: 10.1186/s12991-018-0190-6.
Shah, A., & Northcutt, J. (2018). An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Annals of general psychiatry, 1719. https://doi.org/10.1186/s12991-018-0190-6
Shah, Anish, and Northcutt, Joanne. "An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder." Annals of general psychiatry vol. 17 (2018): 19. doi: https://doi.org/10.1186/s12991-018-0190-6
Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry. 2018 May 11;17:19. doi: 10.1186/s12991-018-0190-6. eCollection 2018. PMID: 29760763; PMCID: PMC5946398.
Copy Download .nbib Format: NLM
Acetylcholinesterase inhibitors in treatment-resistant psychotic depression.

Therapeutic advances in psychopharmacology

Smart C, McAllister-Williams H, Cousins DA.
PMID: 29344344
Ther Adv Psychopharmacol. 2018 Jan;8(1):59-61. doi: 10.1177/2045125317718810. Epub 2017 Jul 10.

Dopamine receptor antagonists can be effective in psychotic depression but response is not assured. Visual hallucinations may arise from a dysregulation of brain cholinergic systems and acetylcholinesterase inhibitors (AChEIs) can treat such hallucinations in dementia with Lewy bodies (DLB)....

Cite
Smart C, McAllister-Williams H, Cousins DA. Acetylcholinesterase inhibitors in treatment-resistant psychotic depression. Ther Adv Psychopharmacol. 2017;8(1):59-61doi: 10.1177/2045125317718810.
Smart, C., McAllister-Williams, H., & Cousins, D. A. (2018). Acetylcholinesterase inhibitors in treatment-resistant psychotic depression. Therapeutic advances in psychopharmacology, 8(1), 59-61. https://doi.org/10.1177/2045125317718810
Smart, Chris, et al. "Acetylcholinesterase inhibitors in treatment-resistant psychotic depression." Therapeutic advances in psychopharmacology vol. 8,1 (2018): 59-61. doi: https://doi.org/10.1177/2045125317718810
Smart C, McAllister-Williams H, Cousins DA. Acetylcholinesterase inhibitors in treatment-resistant psychotic depression. Ther Adv Psychopharmacol. 2018 Jan;8(1):59-61. doi: 10.1177/2045125317718810. Epub 2017 Jul 10. PMID: 29344344; PMCID: PMC5761905.
Copy Download .nbib Format: NLM
Corrigendum to ``The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram'' [Journal of Affective Disorders, 227 (2018) 803-809].

Journal of affective disorders

Vieta E, Sluth LB, Olsen CK.
PMID: 29807616
J Affect Disord. 2018 Aug 15;236:319. doi: 10.1016/j.jad.2018.03.011. Epub 2018 Apr 05.

No abstract available.

Cite
Vieta E, Sluth LB, Olsen CK. Corrigendum to ``The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram'' [Journal of Affective Disorders, 227 (2018) 803-809]. J Affect Disord. 2018;236:319doi: 10.1016/j.jad.2018.03.011.
Vieta, E., Sluth, L. B., & Olsen, C. K. (2018). Corrigendum to ``The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram'' [Journal of Affective Disorders, 227 (2018) 803-809]. Journal of affective disorders, 236319. https://doi.org/10.1016/j.jad.2018.03.011
Vieta, Eduard, et al. "Corrigendum to ``The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram'' [Journal of Affective Disorders, 227 (2018) 803-809]." Journal of affective disorders vol. 236 (2018): 319. doi: https://doi.org/10.1016/j.jad.2018.03.011
Vieta E, Sluth LB, Olsen CK. Corrigendum to ``The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram'' [Journal of Affective Disorders, 227 (2018) 803-809]. J Affect Disord. 2018 Aug 15;236:319. doi: 10.1016/j.jad.2018.03.011. Epub 2018 Apr 05. PMID: 29807616.
Copy Download .nbib Format: NLM
Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission.

Frontiers in pharmacology

Pehrson AL, Pedersen CS, Tølbøl KS, Sanchez C.
PMID: 29559911
Front Pharmacol. 2018 Mar 06;9:162. doi: 10.3389/fphar.2018.00162. eCollection 2018.

Major depressive disorder (MDD) is associated with cognitive impairments that may contribute to poor functional outcomes. Clinical data suggests that the multimodal antidepressant vortioxetine attenuates some cognitive impairments in MDD patients, but the mechanistic basis for these improvements is...

Cite
Pehrson AL, Pedersen CS, Tølbøl KS, et al. Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. Front Pharmacol. 2018;9:162doi: 10.3389/fphar.2018.00162.
Pehrson, A. L., Pedersen, C. S., Tølbøl, K. S., & Sanchez, C. (2018). Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. Frontiers in pharmacology, 9162. https://doi.org/10.3389/fphar.2018.00162
Pehrson, Alan L, et al. "Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission." Frontiers in pharmacology vol. 9 (2018): 162. doi: https://doi.org/10.3389/fphar.2018.00162
Pehrson AL, Pedersen CS, Tølbøl KS, Sanchez C. Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. Front Pharmacol. 2018 Mar 06;9:162. doi: 10.3389/fphar.2018.00162. eCollection 2018. PMID: 29559911; PMCID: PMC5845537.
Copy Download .nbib Format: NLM
Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry

Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A.
PMID: 33549697
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 05.

Gastrointestinal side effects (SEs) are frequently observed in patients with major depressive disorder (MDD) while taking antidepressants and may lead to treatment discontinuation. The aim of this meta-analysis is to provide quantitative measures on short-term rates of gastrointestinal SEs...

Cite
Oliva V, Lippi M, Paci R, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110266doi: 10.1016/j.pnpbp.2021.110266.
Oliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., & Serretti, A. (2021). Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry, 109110266. https://doi.org/10.1016/j.pnpbp.2021.110266
Oliva, Vincenzo, et al. "Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis." Progress in neuro-psychopharmacology & biological psychiatry vol. 109 (2021): 110266. doi: https://doi.org/10.1016/j.pnpbp.2021.110266
Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 05. PMID: 33549697.
Copy Download .nbib Format: NLM
No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR, Mills NT, Fourrier C.
PMID: 34375789
Eur Neuropsychopharmacol. 2021 Dec;53:34-46. doi: 10.1016/j.euroneuro.2021.07.092. Epub 2021 Aug 08.

Given the role of low-grade inflammation in the pathophysiology of major depressive disorder (MDD), anti-inflammatory strategies may improve treatment outcomes in some patients. However, it is controversial whether they can be used as adjunctive treatments and whether pre-treatment levels...

Cite
Baune BT, Sampson E, Louise J, et al. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol. 2021;53:34-46doi: 10.1016/j.euroneuro.2021.07.092.
Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021). No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 5334-46. https://doi.org/10.1016/j.euroneuro.2021.07.092
Baune, Bernhard T, et al. "No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial." European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology vol. 53 (2021): 34-46. doi: https://doi.org/10.1016/j.euroneuro.2021.07.092
Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR, Mills NT, Fourrier C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol. 2021 Dec;53:34-46. doi: 10.1016/j.euroneuro.2021.07.092. Epub 2021 Aug 08. PMID: 34375789.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 122 entries